Indonesia approves Comirnaty as COVID-19 booster vaccine for age group of 16 years and above
0 Comment(s)
Print
E-mail Xinhua, August 2, 2022
JAKARTA, Aug. 2 (Xinhua) -- Indonesia's food and drug authority BPOM has approved the emergency use authorization for Comirnaty as a booster dose of the COVID-19 vaccine for the age group of 16 years and above.
Head of BPOM Penny K. Lukito told local media that the mRNA-platform vaccine, developed by Pfizer in collaboration with BioNTech, is the first vaccine to have received approval for a booster dose for this age group.
The third phase clinical trial on subjects aged 16 years and above showed the effectiveness of the booster vaccine with 95.6 percent efficacy in preventing the COVID-19 infection.
Comirnaty vaccine had received the emergency use approval from Indonesia as a primary vaccine for those aged 12 and above, and as a booster dose for the age group of 18 years and above. Enditem
Go to Forum >>0 Comment(s)